Expanded Treatment Options for Metastatic Pancreatic Cancer: Evidence-Based Updates
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator's Guide (non-certified educational resources)
The goal of this activity is to improve clinicians’ knowledge and competence regarding the treatment, management, and supportive care strategies for metastatic pancreatic cancer.
In the United States, there were an estimated 53,070 new cases of pancreatic cancer in 2016. An estimated 41,780 deaths were expected in the United States in 2016, making pancreatic cancer the fourth leading cause of cancer death in men and women. Approximately 20% of all patients with pancreatic cancer are candidates for curative surgical resection because most patients present with locally advanced or metastatic disease. During the past few decades, little progress has been made in improving outcomes for patients with pancreatic cancer.
Recently, however, some improvement in survival in the metastatic setting has been demonstrated. The US Food and Drug Administration (FDA) has approved nab-paclitaxel in combination with gemcitabine in 2013 as first-line treatment for metastatic disease, and nanoliposomal irinotecan in combination with 5-fluorouracil and leucovorin as second-line treatment for metastatic disease after treatment with a gemcitabine-based chemotherapy was approved in 2015. Several novel agents are also currently being investigated in clinical trials for the treatment of metastatic pancreatic cancer.
In addition, there is strong evidence supporting the role of shared decision making in pancreatic cancer and how this approach can improve patient satisfaction when collaboratively making life-altering decisions about treatment approaches.
This activity will review the latest data for the treatment and management of metastatic pancreatic cancer, and the role of shared decision making in these patients.
- Activity Overview and Introduction to AHRQ SHARE Approach (5 min)
- Overview of Pancreatic Cancer (5 min)
- Current Therapeutic Options for Metastatic Pancreatic Cancer (20 min)
- Adverse Reaction and Side Effect Management, and Supportive Care Strategies (10 min)
- Case Studies: Treatment Selection, Sequencing, and Management of Metastatic Disease (10 min)
- Emerging Therapies for Metastatic Disease (10 min)
- Activity Conclusion and Q&A
This activity is intended for medical oncologists, advanced practice registered nurses, nurses, pharmacists, and other healthcare professionals who treat and manage pancreatic cancer.
At the conclusion of this activity, participants should be better able to:
- Use appropriate therapeutic options for patients with metastatic pancreatic cancer based on current evidence-based clinical guidelines
- Discuss with patients and their families clinical trials that may be an option for treatment of metastatic pancreatic cancer
- Describe the potential clinical practice application of data on agents in late-stage clinical trials for the treatment of metastatic pancreatic cancer
- Identify, monitor, and manage adverse reactions and side effects associated with treatments for metastatic pancreatic cancer
- Provide appropriate palliative and supportive care for patients with metastatic pancreatic cancer and their families
- Use a shared decision-making approach to engage patients and families in decisions about treatment and management of metastatic pancreatic cancer
Andrea Wang-Gillam, MD, PhD
Gerard Blobe, MD, PhD
E. Gabriela Chiorean, MD
|Steven J. Cohen MD|
Chief Division of Medical Oncology
Director, Rosenfeld Cancer Center
Abington Memorial Hospital
Vice-Chair Department of Medical Oncology
Jefferson University Hospital
Sidney Kimmel Cancer Center
Andrew Ko, MD
Caio Max S. Rocha Lima, MD
|Weijing Sun, MD, FACP|
Professor of Medicine
Director, Gastrointestinal Cancer Section
Co-Director, Gastrointestinal Cancer Center of Excellence
University of Pittsburgh/UPMC
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit. UAN 0592-0000-17-002-L01-P .
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Andrea Wang-Gillam, MD, PhD||Andrea Wang-Gillam, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant, Ipsen Pharmaceuticals, Merrimack|
|Gerard Blobe, MD, PhD||Gerard Blobe, MD, PhD reported a financial interest/relationship or affiliation in the form of Consultant, |
Genentech/Roche; Speakers Bureau, Genentech/Roche; Received income in any amount: Genentech/Roche
|E. Gabriela Chiorean, MD||E. Gabriela Chiorean, MD, reported a financial interest/relationship or affiliation in the form of Consultant, |
Pfizer, Inc.; Research grant, Genentech, Inc, Celgene Corp, Genentech, Inc, Ignyta, Novocure, Prism Pharmaceuticals, Inc, Stemline Theraputics, Newlink Genetics, Boehringer Ingelheim
|Steven J. Cohen, MD||Steven J. Cohen, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee, Merck & Co, Inc; Consulting fee, Genentech, Inc; Received income in any amount from, Merrimack Pharmaceuticals|
|Andrew Ko, MD||Andrew Ko, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee, Incyte, ARMO, EMD Serono, Genentech/Roche, Halozyme, Merrimack, Seattle Genetics, New Beta Innovation; Contracted research, Merrimack, Aduro Biotech, Celgene|
|Caio Max S. Rocha Lima, MD||Caio Max S. Rocha Lima, MD, has no real or apparent conflicts of interest to report|
|Weijing Sun, MD, FACP||Weijing Sun, MD, FACP, has no real or apparent conflicts of interest to report|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda-Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Merrimack Pharmaceuticals, Inc.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Attendance